While retail was busy averaging down into Target this month, watching their accounts bleed every time the stock dropped another tick, something very different happened in the private market. Anduril Industries — the defense tech company founded by Palmer Luckey — just closed a $5 billion Series H funding round at a $61 billion valuation. That's double what it was worth less than a year ago. From $4.7 billion in 2021 to $61 billion last week. And not a single retail trader on Robinhood could touch a share of it.
This is the Hidden Stock Market. And it is making the rich richer in real time while the public tape stays in the gutter.
Did You Forget To Grab This? (Ad)
If you still haven't downloaded my $29.97 "Simple Options Trading For Beginners" guide...
...please take a few seconds and download a free copy right now before your temporary download link expires.
I charge $29.97 for this guide on my website, so do yourself a favor and download your free copy now...
That way, when the link expires, you'll have a copy on your computer already.
OK?
P.S. Go here to save a free copy of my $29.97 "Simple Options Trading For Beginners" guide to your computer before your link expires.
The Deal Breakdown
Here's what just printed in the private market:
Company: Anduril Industries
Round: Series H, $5 billion raised
Valuation: $61 billion (up from $30.5B in mid-2025)
Lead investors: Thrive Capital, Andreessen Horowitz
2025 revenue: approx. $2 billion
Recent contract: $1.8B Andromeda program for the U.S. Air Force
Now compare that with what retail has been doing on the public side. TGT was trading at $133 last summer, collapsed to $83 at the lows, and is grinding back near $126 — but net income just dropped from $1.04B to $781M year-over-year, and EPS got cut in half. Different market. Different result. Different outcome.
The Mechanics
The Hidden Stock Market doesn't move the way the public tape moves. Valuations are negotiated, not auctioned. There's no algo getting triggered by a CPI print. There's no Robinhood crowd panicking out of positions. The check writers in private rounds aren't trying to "time" anything — they're sizing into a thesis that won't print on a chart for another 18 months.
Here's how the compounding actually works:
A venture firm writes the check at a marked valuation
That valuation becomes the new floor for the next round
The next round prices higher, marking up the first investor's position
Repeat every 12–18 months until exit or IPO
There is no drawdown. There is no margin call. There is no overnight gap. There is just relentless upward marking, while the public market eats every tick of risk in real time. That's how Anduril went from $4.7B to $61B in five years — and the average retail account didn't get to participate in a single dollar of it.
The Institutional Context
The same institutions selling public stocks like TGT into your buying are turning around and writing 9-figure checks into Anduril. That's not a conspiracy — it's a balance-sheet reality. Look at where the smart money is actually allocating capital this cycle:
Defense tech (Anduril at $61B, Shield AI scaling, Saronic raising)
AI infrastructure (private rounds at premium marks every quarter)
Critical hardware (autonomous systems, drone manufacturing, sensor networks)
While Target fights tariffs and a soft consumer, while retail traders argue about whether $120 is "cheap" or "expensive," the private books at Andreessen Horowitz and Thrive Capital just doubled their Anduril mark with a single funding round. That move alone — for the early checks — outearned years of public market returns in a single afternoon.
The Risk Asymmetry
Here's the part that should make you furious. When you buy 100 shares of TGT and the stock falls 35% on a guidance cut, you eat 100% of that loss the same day. There is no buffer. There is no escape hatch. The public market is designed to deliver pain at full speed.
Now look at how the other side experiences risk:
Public stock buyer in TGT: full mark-to-market downside every minute the market is open
Private round investor in Anduril: position marked only at funding events, almost always at higher levels
Net result: one investor "lost" 35% on the day; the other "made" 100% on the year
That isn't a fair fight. That's a structural advantage hidden inside the accreditation rules — and it's the whole reason the wealth gap keeps widening.
Hedge Fund Watchlist
For the public side of the book, here's what's on the radar right now:
GSK 8/21/2026 $55 Calls at $1.20 — pharma rotation play with cheap premium
CHWY 11/20/2026 $32.5 Calls at $1.05 — consumer name with quiet accumulation
ITW 9/18/2026 $280 Calls at $3.30 — industrials base-building under the radar
Three names, three sectors, three small premiums. The blueprint is the same one the private market uses — defined risk, asymmetric payoff, time to be right. You don't need to be Andreessen Horowitz to copy the structure. You just need to size positions where the worst case is capped and the best case is wide open.
The Hidden Stock Market isn't hidden because it's complicated. It's hidden because access to it is the entire point. Anduril at $61B is the proof. Retail will never see that share. Retail will only see the headlines, the IPO 18 months from now, and the chart that's already gone vertical before they can click buy.
You have two paths from here:
Keep chasing TGT lower and praying retail names mean-revert
Stop fighting the structure and start using contracts that mimic the same risk profile the private market enjoys
The rich don't get richer by accident. They get richer by holding instruments retail can't even see.
Stop chasing dips. Start reading the structure.
Disclaimer: This content is for educational purposes only and does not constitute financial advice. Options trading involves risk, and not all trades will be profitable. Always manage risk responsibly.
